Market Research and Forecast of Antineoplastic Drugs in China 2016-2021

Market Research and Forecast of Antineoplastic Drugs in China 2016-2021

  • January 2017 •
  • 51 pages •
  • Report ID: 4696059 •
  • Format: PDF
Antineoplastic drugs develop from traditional single antineoplastic drug towards a new type of antineoplastic drug aiming at functions at multiple links. Research and development of antineoplastic drugs have stepped in to a new stage.

Till now, there are nearly four million cases of new tumors in China every year. With aging of population, environmental pollution caused by industrialization and lifestyles changed by factors like urbanization, malignant tumors replace cardiovascular diseases and become the top killer in China, taking 25% in total deaths.

For the increasing incidence of tumors, released needs for antineoplastic drugs and improving technologies for the drugs, output of the drugs will further increase in China. According to statistics of ASKCI, in 2015, total output of antineoplastic drugs was about 440 tonnes, with the market scale of nearly RMB100 billion. Sales of transnational enterprise were more centered and generally focused on promotion of their key products. While domestic enterprises applied the strategy of sales in a wide range.

In 2021, the forecast of China antineoplastic drug market will reach more than RMB250 billion, relatively conservative compared to global market. Except adjuvant drugs like immunosuppressant, anti-metabolic will have the most market shares, with a stable growth. The second will be botanical preparations, remaining a relatively fast growth. Growth of alkylating agents, antibiotics and platinum drugs will tend to slow. As for targeted drugs, it is predicted that there is a large potential in independent R&D of targeted drugs, with the consideration of more supports by the government, and which will become the most important field leading domestic market of antineoplastic drugs.